TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18339132

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sirolimus (SRL) loading dose of 15 mg, 5 mg/d till day 7 and 2 mg/d thereafter
Number of subjects: 100
Study: 16542443

Group type: EXPERIMENTAL
Intervention: Solution-focused follow-up (n = 53)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Treatment as usual (n = 50)
Number of subjects: 703
Study: 12685885

Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir 10 mg via Diskhaler twice daily for 5 days
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 11105734

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily, titrated to a maximum of 200 mg daily)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 9365042

Group type: EXPERIMENTAL
Intervention: Serum anti‐p53 antibody positivity
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Bilirubin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: p53 antibody
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Alpha‐fetoprotein (AFP)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Indocyanine green retention time at 15 min (ICG)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Bilirubin and p53 antibody
Number of subjects: 86
Study: 1556197

Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy (SI)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Perceptual-Motor Training (PM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 103
Study: 30955980

Group type: EXPERIMENTAL
Intervention: 1 booster dose of 45 mcg of IIV1 A/H7N9 hemagglutinin
Number of subjects: 27

Group type: COMPARATOR
Intervention: AS03-adjuvanted IIV1 A/H7N9
Number of subjects: 27
Study: 29719927

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 142

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Number of subjects: 142
Study: 27183909

Group type: EXPERIMENTAL
Intervention: R-EPOCH
Number of subjects: 176

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 176
Study: 24434889

Group type: EXPERIMENTAL
Intervention: Upper thoracic manipulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo procedure in the thoracic region
Number of subjects: 32
Study: 22974273

Group type: EXPERIMENTAL
Intervention: RAD-I (structured interview assessing the patient's perspective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAD-Q (questionnaire assessing the clinician's perspective)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RAD (both RAD-I and RAD-Q)
Number of subjects: 0
Study: 19892414

Group type: EXPERIMENTAL
Intervention: Oral care intervention (professional oral care from a dentist three times a week for 1 year)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no oral care intervention)
Number of subjects: 53
Study: 17109723

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 100
Study: 16198248

Group type: EXPERIMENTAL
Intervention: QRS duration <120 ms
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: QRS duration 120‐159 ms
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: QRS duration > or = 160 ms
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 248
Study: 12391509

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (220 micro g/puff) at 2 puffs twice daily for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9927363

Group type: EXPERIMENTAL
Intervention: CT + CPAP (Continuous Positive Airway Pressure)
Number of subjects: 105

Group type: COMPARATOR
Intervention: CT (Conservative Treatment)
Number of subjects: 105
Study: 7484334

Group type: EXPERIMENTAL
Intervention: Confederate beverage choice and personal alcohol expectancy (social/physical pleasure)
Number of subjects: 133
Study: 1962805

Group type: EXPERIMENTAL
Intervention: Structured hypertension care
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Control group (no structured hypertension care)
Number of subjects: 1169
Study: 6165189

Group type: EXPERIMENTAL
Intervention: 8-MOP brand with high maximum concentration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 8-MOP brand with medium maximum concentration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 8-MOP brand with low maximum concentration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All 8-MOP brands
Number of subjects: 7
Study: 31021469

Group type: EXPERIMENTAL
Intervention: 1 mm abutment height group
Number of subjects: 33

Group type: COMPARATOR
Intervention: 3 mm abutment height group
Number of subjects: 33
Study: 28727632

Group type: EXPERIMENTAL
Intervention: Endoscopic Totally Extraperitoneal (TEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open Stoppa inguinal hernia repair
Number of subjects: 0
Study: 26077218

Group type: EXPERIMENTAL
Intervention: Cumulative assessment (n=25)
Number of subjects: 78

Group type: COMPARATOR
Intervention: End-of-course assessment (n=37)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cumulative assessment
Number of subjects: 78
Study: 23506666

Group type: EXPERIMENTAL
Intervention: LACE DVD training for new HA users
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LACE DVD training for experienced HA users
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (new HA users with no training)
Number of subjects: 29
Study: 21153417

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day 3 hours before racing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 19321312

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 1742

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1742
Study: 17367707

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA)‐rich diet (38% fat and 20% SFA)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Carbohydrate (CHO)‐rich diet (30% fat and 55% carbohydrate)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Monounsaturated fatty acid (MUFA)‐rich diet (38% fat and 22% MUFA)
Number of subjects: 97
Study: 15286114

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11777296

Group type: EXPERIMENTAL
Intervention: Selective α1-blockers
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (placebo or active treatment arms)
Number of subjects: 22
Study: 9417523

Group type: EXPERIMENTAL
Intervention: Filtered, pooled platelet concentrates from random donors (F-PC)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Ultraviolet B-irradiated, pooled platelet concentrates from random donors (UVB-PC)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Filtered platelets obtained by apheresis from single random donors (F-AP)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Unmodified, pooled platelet concentrates from random donors (control)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: All groups (F-PC, UVB-PC, F-AP)
Number of subjects: 530
Study: 7951680

Group type: EXPERIMENTAL
Intervention: Combination of oral physostigmine plus clonidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral physostigmine alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3295935

Group type: EXPERIMENTAL
Intervention: Clonidine (500-700 micrograms/day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Discontinuation of clonidine
Number of subjects: 4
Study: 29249618

Group type: EXPERIMENTAL
Intervention: Guided imagery combined with relaxation therapy and other complementary therapies (e.g., hand and foot 'M' technique, education on pain management, relaxation exercises, respiration exercises, meditation, soothing music, nature sounds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0
Study: 29100709

Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 3646

Group type: COMPARATOR
Intervention: Influenza vaccine (Cohort 2)
Number of subjects: 3646
Study: 26745101

Group type: EXPERIMENTAL
Intervention: Blood test (methylated BCAT1/IKZF1) offered to FIT non-participants
Number of subjects: 600

Group type: COMPARATOR
Intervention: FIT (faecal immunochemical test)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Blood test offered to those who indicated FIT was inappropriate
Number of subjects: 600
Study: 23621624

Group type: EXPERIMENTAL
Intervention: Peer‐led, small‐group, structured writing using film clips from Women's Voices Women's Lives as a writing prompt
Number of subjects: 110
Study: 21668963

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/d
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo (switched to duloxetine at Week 12)
Number of subjects: 530
Study: 19502038

Group type: EXPERIMENTAL
Intervention: Lightwand-guided nasotracheal intubation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laryngoscopy-assisted nasotracheal intubation
Number of subjects: 60
Study: 16862474

Group type: EXPERIMENTAL
Intervention: Continuous intracutaneous suture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Donati stitches
Number of subjects: 80
Study: 15298240

Group type: EXPERIMENTAL
Intervention: High group (maintained PP between 60 and 80 mmHg with phenylephrine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low group (no specific intervention mentioned)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study: 11532844

Group type: EXPERIMENTAL
Intervention: Interactive multimedia decision aid
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 14685376

Group type: EXPERIMENTAL
Intervention: Capillary puncture (P)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Alcohol swab friction (F)
Number of subjects: 133
Study: 12959269

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg every 12 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg every 12 h
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of metoprolol and nicardipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2888152

Group type: EXPERIMENTAL
Intervention: Quazepam (15 or 30 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 or 1.0 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31677351

Group type: EXPERIMENTAL
Intervention: Summarizing for a professor/boss
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Summarizing for an acquaintance
Number of subjects: 279
Study: 31471690

Group type: EXPERIMENTAL
Intervention: Active video games (n=53)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (n=53)
Number of subjects: 106
Study: 27826671

Group type: EXPERIMENTAL
Intervention: Onsite mentoring
Number of subjects: 30

Group type: COMPARATOR
Intervention: Offsite mentoring
Number of subjects: 30
Study: 25951630

Group type: EXPERIMENTAL
Intervention: Modified Yangyin Yiqi Huoxue Recipe (YYHR)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Xueshuan Xinmaining (Control)
Number of subjects: 312
Study: 24823426

Group type: EXPERIMENTAL
Intervention: Biolimus A9-eluting stent (BES)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (PtCr-EES)
Number of subjects: 500
Study: 22517425

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with gemcitabine and cisplatin
Number of subjects: 11
Study: 19744867

Group type: EXPERIMENTAL
Intervention: Saphenous stripping and phlebectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided foam sclerotherapy
Number of subjects: 60
Study: 17322150

Group type: EXPERIMENTAL
Intervention: golimumab (0.1, 0.3, 1, 3, 6, or 10 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 15564757

Group type: EXPERIMENTAL
Intervention: Topical brinzolamide
Number of subjects: 20
Study: 11595118

Group type: EXPERIMENTAL
Intervention: Postmastectomy chest wall radiotherapy (PMCWRT)
Number of subjects: 0
Study: 10223678

Group type: EXPERIMENTAL
Intervention: Reading of tongue twister with delayed auditory feedback (DAF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading of tongue twister without DAF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spelling of alphabet in reverse order
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reading of tongue twister with DAF in second test
Number of subjects: 0
Study: 7603218

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin supplement (1 mg vitamin B12, 1.1 mg folate, 5 mg vitamin B6)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin supplement
Number of subjects: 285
Study: 2665884

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg i.m. every 3 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 39
Study: 391427

Group type: EXPERIMENTAL
Intervention: Fixed alternate treatment program involving Adriamycin and L‐PAM and Cytoxan, 5‐Fluorouracil, and Prednisone
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Fixed alternate treatment program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Induction treatment programs (Adriamycin and L‐PAM versus Cytoxan, 5‐Fluorouracil, and Prednisone)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Fixed alternating treatment group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Both treatment regimens
Number of subjects: 128
Study: 31994720

Group type: EXPERIMENTAL
Intervention: Intravenous ET-1 infusion (8 ng/kg/min for 20 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study: 31149923

Group type: EXPERIMENTAL
Intervention: Social media promotion (SoMe) using Twitter, Facebook, and LinkedIn for 30 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: No social media promotion (NoSoMe)
Number of subjects: 68
Study: 29359166

Group type: EXPERIMENTAL
Intervention: Face-to-face education group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Telephone-based education group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 26082203

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.5 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.25 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Postoperative analgesia after rotator cuff repair vs subacromial decompression
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Age effect on postoperative analgesia
Number of subjects: 240
Study: 22987897

Group type: EXPERIMENTAL
Intervention: Parent education and behaviour management (n = 35)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Parent education and counselling (n = 35)
Number of subjects: 105
Study: 22503223

Group type: EXPERIMENTAL
Intervention: PCST+BWM
Number of subjects: 232

Group type: COMPARATOR
Intervention: PCST-only
Number of subjects: 232

Group type: COMPARATOR
Intervention: BWM-only
Number of subjects: 232

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 232
Study: 19301940

Group type: EXPERIMENTAL
Intervention: Klarithran MR (generic formulation of clarithromycin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Klacid XL (originator formulation of clarithromycin)
Number of subjects: 0
Study: 17709915

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily for 3 months
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg daily for 3 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (36 healthy subjects)
Number of subjects: 66
Study: 14634716

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11424313

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 28
Study: 9663813

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg with quinidine 50 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7828564

Group type: EXPERIMENTAL
Intervention: Postoperative endoscopic surveillance program (compliant group, n=88)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Noncompliant group (n=124)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Asymptomatic tumor recurrences (both compliant and noncompliant)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Symptomatic tumor recurrences (both compliant and noncompliant)
Number of subjects: 212
Study: 2595270

Group type: EXPERIMENTAL
Intervention: Citrate (46 mmol/l) in effervescent glucose-electrolyte solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betaine (36 mmol/l) in effervescent glucose-electrolyte solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bicarbonate-containing oral rehydration solution
Number of subjects: 0
Study: 129056

Group type: EXPERIMENTAL
Intervention: Ivosin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30396100

Group type: EXPERIMENTAL
Intervention: Modified pectoral nerve block (PECS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Erector spinae plane block (ESP)
Number of subjects: 38
Study: 29241890

Group type: EXPERIMENTAL
Intervention: Test-directed care using Oncotype DX™
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (chemotherapy for all)
Number of subjects: 0
Study: 26210348

Group type: EXPERIMENTAL
Intervention: Smoking cessation (abstainers)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Continued smoking (control group)
Number of subjects: 380
Study: 24231479

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study: 22105586

Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no Oseltamivir)
Number of subjects: 19
Study: 19175892

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 17379291

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Dietary omega-6 fatty acid restriction
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Overall fatty acid exposure (plasma levels, dietary intake, compliance)
Number of subjects: 516
Study: 15229773

Group type: EXPERIMENTAL
Intervention: Removal of hypertrophied anal papillae or fibrous polyps after sphincterotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Only sphincterotomy
Number of subjects: 80
Study: 11453509

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) nasal spray, 42 micrograms/spray, administered intranasally twice daily for two weeks.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline nasal spray (placebo), administered intranasally twice daily for two weeks.
Number of subjects: 6
Study: 9462565

Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy (DCA)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Other devices
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Stand-alone balloon use
Number of subjects: 1465
Study: 7846938

Group type: EXPERIMENTAL
Intervention: Quinidine (1,500 mg/day for days 1-3, then 1,500 mg + verapamil 240 mg/day for days 4-6)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Quinidine and verapamil (1,500 mg + 240 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amiodarone (1,200 mg/day intravenously for days 1-3, then 800 mg/day orally for days 4-14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quinidine and verapamil (480 mg/day + 240 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 40
Study: 3276824

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 113

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CAFVP followed by surgery or RT)
Number of subjects: 113
Study: 31564697

Group type: EXPERIMENTAL
Intervention: Serum MMP‐9 levels in patients with PSD (658.8 ng/mL)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Highest MMP‐9 quartile
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: 1 standard deviation increase in log-MMP‐9
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: MMP‐9 added to conventional risk factors model
Number of subjects: 558
Study: 30055336

Group type: EXPERIMENTAL
Intervention: Weight loss treatment delivered by peer coaches over 18 months
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Weight loss treatment delivered by peer coaches
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Peer coach intervention
Number of subjects: 375
Study: 26977856

Group type: EXPERIMENTAL
Intervention: 12 months' self-referral reminder
Number of subjects: 155
Study: 24852376

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 600 mg twice daily for 5 days
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 300 mg twice daily for 5 days
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 22209057

Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT)
Number of subjects: 8
Study: 19682359

Group type: EXPERIMENTAL
Intervention: Rapid reduction with nicotine patches and acute nicotine replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard abrupt cessation with nicotine patches only
Number of subjects: 0
Study: 17633358

Group type: EXPERIMENTAL
Intervention: Wenshen Huatan Recipe (WHR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional and symptomatic treatment (Control)
Number of subjects: 60